Retatrutide appears to be a new pharmaceutical in the fight against obesity. This revolutionary drug, categorized as a dual GLP-1 and GIP receptor agonist, exhibits promising results in research studies. By activating these receptors, Retatrutide reduces hunger pangs, {promotesenergy expenditure, and ultimately contributes to significant weight los